Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations

References

• BeusterienKGrinspanJKuchukIUse of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effectsOncologist2014192 127 13424473225
   PubMed Web of Science ®Google Scholar
• SunCCBodurkaDCWeaverCBRankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupport Care Cancer2005134 219 22715538640
   PubMed Web of Science ®Google Scholar
• VidallCFernandez-OrtegaPCortinovisDJahnPAmlaniBScotteFImpact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational surveySupport Care Cancer20152311 3297 330525953380
   PubMed Web of Science ®Google Scholar
• HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med200835823 2482 249418525044
   PubMed Web of Science ®Google Scholar
• NavariRMThe safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomitingExpert Opin Drug Saf2016153 343 35626699406
   PubMed Web of Science ®Google Scholar
• RuddJAAndrewsPLMechanisms of acute, delayed and anticipatory emesis induced by anticancer therapiesHeskethPJManagement of nausea and vomiting in cancer and cancer treatmentSudbury, MAJones and Bartlett Publishers2005 15 66
   Google Scholar
• SaitoRTakanoYKamiyaHORoles of substance P and NK(1) receptor in the brainstem in the development of emesisJ Pharmacol Sci2003912 87 9412686752
   PubMed Web of Science ®Google Scholar
• JordanKJahnFAaproMRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewAnn Oncol2015266 1081 109025755107
   PubMed Web of Science ®Google Scholar
• NavariRMAaproMAntiemetic prophylaxis for chemotherapy-induced nausea and vomitingN Engl J Med201637414 1356 136727050207
   PubMed Web of Science ®Google Scholar
• BaschEPrestrudAAHeskethPJAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol20112931 4189 419821947834
   PubMed Web of Science ®Google Scholar
• HeskethPJBohlkeKLymanGHAntiemetics: American Society of Clinical Oncology focused guideline updateJ Clin Oncol2016344 381 38626527784
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology: antiemesis Version 2NCCN2016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdfAccessed February 3, 2017
   Google Scholar
• RoilaFMolassiotisAHerrstedtJ2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patientsAnn Oncol201627suppl 5 v119 v13327664248
   PubMed Web of Science ®Google Scholar
• BarbourSYCorticosteroids in the treatment of chemotherapy-induced nausea and vomitingJ Natl Compr Canc Netw2012104 493 49922491048
   PubMed Web of Science ®Google Scholar
• NandeeshBRReddyTMChemotherapy induced nausea & vomiting (CINV)Int J Basic Clin Pharmacol201213 125 131
   Google Scholar
• NavariRMQinRRuddyKJOlanzapine for the prevention of chemotherapy-induced nausea and vomitingN Engl J Med20163752 134 14227410922
   PubMed Web of Science ®Google Scholar
• WangXZhangZYAroraSA single-dose bioequivalence study of rolapitant following oral and intravenous administration in healthy volunteersSupport Care Cancer201624suppl 1 S74
   Google Scholar
• DuffyRAMorganCNaylorRRolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferretsPharmacol Biochem Behav20121021 95 10022497992
   PubMed Web of Science ®Google Scholar
• RizziACampiBCamardaVIn vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist NetupitantPeptides2012371 86 9722732666
   PubMed Web of Science ®Google Scholar
• HuskeySEDeanBJBakhtiarRBrain penetration of aprepitant, a substance P receptor antagonist, in ferretsDrug Metab Dispos2003316 785 79112756213
   PubMed Web of Science ®Google Scholar
• WangXZhangZYPowersDWangJLuSKansraVRolapitant absolute bioavailability and PET imaging studies in healthy adult volunteersClin Pharmacol Ther Epub2017131
   Web of Science ®Google Scholar
• BergstromMHargreavesRJBurnsHDHuman positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitantBiol Psychiatry20045510 1007 101215121485
   PubMed Web of Science ®Google Scholar
• HargreavesRImaging substance P receptors (NK1) in the living human brain using positron emission tomographyJ Clin Psychiatry200263suppl 11 18 24
   PubMed Web of Science ®Google Scholar
• SpinelliTCalcagnileSGiulianoCNetupitant PET imaging and ADME studies in humansJ Clin Pharmacol2014541 97 10824122871
   PubMed Web of Science ®Google Scholar
• Van LaereKDe HoonJBormansGEquivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imagingClin Pharmacol Ther2012922 243 25022739139
   PubMed Web of Science ®Google Scholar
• Varubi™ (rolapitant) tablets for oral use [package insert]Waltham, MATESARO, Inc.2015
   Google Scholar
• ZhangZYWangXPowersDAbsorption, metabolism, and excretion of rolapitant, a highly selective and long-acting NK-1 antagonist, in healthy volunteersDrug Metab Rev201648suppl 1 50
   Google Scholar
• Akynzeo^® (netupitant and palonosetron) capsules, for oral use [package insert]SwitzerlandHelsinn Healthcare SA2015
   Google Scholar
• Emend^® (aprepitant) capsules and Emend^® for oral suspension [package insert]Whitehouse Station, NJMerck Sharp & Dohme Corp.2015
   Google Scholar
• Emend (fosaprepitant dimeglumine) for injection, for intravenous use [package insert]Whitehouse Station, NJMerck Sharp & Dohme Corp.2016
   Google Scholar
• MajumdarAKHowardLGoldbergMRPharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteersJ Clin Pharmacol2006463 291 30016490805
   PubMed Web of Science ®Google Scholar
• Akynzeo 300 mg/0.5 mg hard capsulesSummary of product characteristicsHelsinn Birex Pharmaceuticals Ltd Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003728/WC500188432.pdfAccessed April 3, 2017
   Google Scholar
• PomaAChristensenJPentikisHAroraSHedleyMRolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrateSupport Care Cancer201321suppl 1 S154
   Google Scholar
• WangJWangXZhangZYEffects of rolapitant administered intravenously on the pharmacokinetics of digoxin (P-gp) and sulfasalazine (BCRP) in healthy volunteersSupport Care Cancer201624suppl 1 S89
   Google Scholar
• SanchezRIWangRWNewtonDJCytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitantDrug Metab Dispos20043211 1287 129215304427
   PubMed Web of Science ®Google Scholar
• AaproMSWalkoCMAprepitant: drug-drug interactions in perspectiveAnn Oncol20102112 2316 232320488873
   PubMed Web of Science ®Google Scholar
• ShadleCRLeeYMajumdarAKEvaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activityJ Clin Pharmacol2004443 215 22314973304
   PubMed Web of Science ®Google Scholar
• MajumdarAKMcCreaJBPanebiancoDLEffects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probeClin Pharmacol Ther2003742 150 15612891225
   PubMed Web of Science ®Google Scholar
• LanzarottiCRossiGEffect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasoneSupport Care Cancer20132110 2783 279123729226
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study GroupJ Clin Oncol20032122 4112 411914559886
   PubMed Web of Science ®Google Scholar
• Poli-BigelliSRodrigues-PereiraJCaridesADAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer20039712 3090 309812784346
   PubMed Web of Science ®Google Scholar
• GrallaRJde WitRHerrstedtJAntiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trialsCancer20051044 864 86815973669
   PubMed Web of Science ®Google Scholar
• RapoportBLJordanKBoiceJAAprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind studySupport Care Cancer2010184 423 43119568773
   PubMed Web of Science ®Google Scholar
• SaitoHYoshizawaHYoshimoriKEfficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialAnn Oncol2013244 1067 107323117073
   PubMed Web of Science ®Google Scholar
• WeinsteinCJordanKGreenSASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trialAnn Oncol2016271 172 17826449391
   PubMed Web of Science ®Google Scholar
• GrunbergSChuaDMaruASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASEJ Clin Oncol20112911 1495 150121383291
   PubMed Web of Science ®Google Scholar
• AaproMRugoHRossiGA randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnn Oncol2014257 1328 133324603643
   PubMed Web of Science ®Google Scholar
• HeskethPJRossiGRizziGEfficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly-emetogenic chemotherapy: a randomized dose-ranging pivotal studyAnn Oncol2014257 1340 134624608196
   PubMed Web of Science ®Google Scholar
• RapoportBLChasenMRGridelliCSafety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trialsLancet Oncol2015169 1079 108926272769
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSModianoMRRapoportBLSafety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trialLancet Oncol2015169 1071 107826272768
   PubMed Web of Science ®Google Scholar
• RapoportBSchwartzbergLChasenMEfficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapyEur J Cancer201657 23 3026851398
   PubMed Web of Science ®Google Scholar
• SchwartzbergLNavariRAroraSPowersDJordanKRapoportBRolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancerPoster presented at: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology annual meeting on supportive care in cancerJune 25, 2016Adelaide, Australia
   Google Scholar
• NavariRJordanKRapoportBLEfficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancersPoster presented at: European Society for Medical OncologyOctober 9, 2016Copenhagen, Denmark
   Google Scholar
• NavariRRapoportBAroraSPowersDJordanKSchwartzbergLRolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with lung cancerPoster presented at: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology annual meeting on supportive care in cancerJune 25, 2016Adelaide, Australia
   Google Scholar
• AaproMAroraSPowersDRolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients aged <65 vs ≥ 65 yearsPoster presented at: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology annual meeting on supportive care in cancerJune 23, 2016Adelaide, Australia
   Google Scholar
• AaproMSAroraSPowersDEfficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patientsPoster presented at: European Society for Medical OncologyOctober 9, 2016Copenhagen, Denmark
   Google Scholar